Navigation Links
YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference
Date:10/1/2010

MISSISSAUGA, ON, Oct. 1 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), today announced it will present preclinical results for its CYT387 JAK1/JAK2 inhibitor program demonstrating that CYT387 possesses an excellent enzymatic potency and selectivity profile which may provide significant clinical advantages. CYT387 is currently being investigated in a Phase I/II clinical study at Mayo Clinic in patients with myelofibrosis. The results will be presented in a poster session at the European School of Haematology International (ESH) International Conference on Myeloproliferative Neoplasms in Albufeira, Portugal held from September 30-October 2, 2010.

"The ESH International Conference showcases leading research in the area of hematology and our participation among other highly-regarded hematological programs highlights the significance of our CYT387 program, which compares very favorably with other JAK inhibitors" said Dr. Nick Glover, President and COO of YM BioSciences. "The encouraging progress our JAK1/JAK2 inhibitor, CYT387, has been showing in the clinic is further reinforced by these data demonstrating that our product may have competitive advantages over other JAK inhibitors currently in development. We look forward to the American Society of Hematology (ASH) meeting in Orlando, Florida, in early December 2010, where detailed preliminary clinical data for CYT387 are expected to be presented."

The ESH poster will be presented at 5:30pm on Saturday, 2nd October. An online version of the poster will be available on the YM BioSciences website at www.ymbiosciences.com.

About YM BioSciences

YM BioSciences Inc. is a drug development company advancing three clinical-stage products: CYT387, a small molecule, dual inhibitor of JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a potent vascular disrupting agent (VDA).

CYT387 is an orally adm
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. YM BioSciences licensee Pulmokine awarded NIH funding to develop small molecule drugs for pulmonary hypertension
2. YM BioSciences reports fiscal year end 2010 operational and financial results
3. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
4. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
5. Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC
6. Signum Biosciences Names Braham Shroot as Chief Executive Officer
7. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
8. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
9. Ambit Biosciences Announces Transition in Company Leadership
10. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
11. Calithera Biosciences Closes $40 Million in Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 Working in collaboration with ... London , Richmond Pharmacology is the first ... 3 study for an investigational RNAi therapeutic being developed for ... the nerves and heart. Read press release ... Based at St Georges University of London ...
(Date:3/26/2015)... 2015 PRC Clinical, a Silicon-Valley based ... management and executive appointments effective immediately. , Mike Catelani ... and member of the Board of Directors. Daniel Head ... Sue Dowden will assume the position of Senior Director ... Operations Officer (COO), has been appointed to the position ...
(Date:3/26/2015)... 2015 Neogen Corporation (NASDAQ: NEOG ) ... quarter of fiscal 2015, which ended Feb. 28, increased ... $6,575,000. Earnings per share in the current quarter were ... net income increased 17% over prior year to $24,142,000, ... per share, for the same period a year ago. ...
(Date:3/26/2015)... 26, 2015 WriteResult, a premier provider ... from Yale University’s School of Public Health and New ... during a 4 month-long project. The goal of the ... income families with free access to fresh produce and ... health concerns like high blood pressure, diabetes and weight ...
Breaking Biology Technology:PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3
... RICHMOND, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Scientists ... by Sangamo BioSciences, Inc., (Nasdaq: SGMO ) to ... cells (hESCs) and induced pluripotent stem cells (hiPSCs). Human ESCs ... Scientists also hope to use these cells therapeutically in ...
... , CRANBURY, N.J., Sept. 8, Palatin Technologies, ... its fourth quarter and fiscal year ended June 30, 2009. ... million, compared to $11.5 million for year ended June 30, 2008. ... was $4.8 million, or $(0.06) per basic and diluted share, compared ...
... ... which is also ranked as one of Britain’s most respected companies, has singled out ... , ... 8, 2009 -- Thomson Reuters, one of the world’s largest stock market analytics firms ...
Cached Biology Technology:Sangamo's Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells 2Sangamo's Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells 3Sangamo's Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells 4Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 2Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 3Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 4Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 5Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 6Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 7Reuters Highlights NutraPharma Financial Giant Predicts NutraPharma (OTCBB: NPHC) Shares Likely to Outperform the Market 2
(Date:3/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) ... Global Strategic Business Report" report to their offering. ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... of World. Annual estimates and forecasts are provided ...
(Date:3/19/2015)... Conn. , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... in a news clip that aired this week on ... ) . In a segment "The Next Great ... wallet ,a new way to pay, and ,a really big ...
(Date:3/17/2015)... 2015 Emotient, the leader in facial ... general availability of Emotient Analytics , the ... of facial expressions. The system analyzes videos of ... and services. It delivers audience response metrics - ... as derived from facial evidence of emotional states. ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... SACRAMENTO, Calif. -- The University of California, Davis, and ... have signed a historic agreement that will change the ... states, and foster critical breakthroughs in the areas of ... new partnership will establish a state-of-the-art BGI sequencing facility ...
... In an experiment on rats, European researchers have proved ... cause to the stomach mucous membrane. Published in the ... to improving the treatment of stomach ulcers. A ... the protecting effect that strawberries have in a mammal ...
... era of environmental consciousness, many buildings are being outfitted to ... literally. Elizabeth Demaray, an associate professor of fine arts, ... skyscrapers to counteract the lack of native vegetation found in ... part of New York,s Art in Odd Places Festival from ...
Cached Biology News:UC Davis and BGI announce partnership to establish state-of-the-art genome center in Sacramento 2UC Davis and BGI announce partnership to establish state-of-the-art genome center in Sacramento 3Strawberries protect the stomach from alcohol 2Rutgers professor uses lichen to help cities go green 2Rutgers professor uses lichen to help cities go green 3
Prostaglandin E2 Luminex Standard Product Lines: Unspecified...
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
ERalpha (Ser 104/106)...
... Phosphatase, Calf Intestinal (CIAP), catalyzes the hydrolysis ... ribo- and deoxyribonucleoside triphosphates. This enzyme is ... linearized cloning vector DNA by removing phosphate ... be used for the dephosphorylation of 5 ...
Biology Products: